Metrics as of 10/13/2026, 06:55 PM (Berlin time), refresh in progress.
NervGen Pharma Stock
NervGen Pharma Corp. Common stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Adam H. Rogers
- Employees
- 8
- Market cap
- $138 M
- IPO
- 08/02/2021
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the…
NervGen Pharma stock: price history
1D
-2.5%
1W
-3.6%
1M
-23.0%
6M
-59.7%
YTD
-69.9%
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~22% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about NervGen Pharma
Analyst assessment of NervGen Pharma
PRICE TARGET LOW
US$12.00
CONSENSUS
US$12.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 14/07/2026
NervGen Pharma stock metrics
P/E
-9.25
P/B
108.37
EV/EBITDA
-20.31
RETURN ON EQUITY
-173.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
78.3%
FLOAT SHARES
64,353,940
AVG. DAILY VOLUME (30D)
482,405
Institutional holders
Comparable stocks
Frequently asked questions about NervGen Pharma stock
What does NervGen Pharma do?
NervGen Pharma Corp. Common stock is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Adam H. Rogers, the company employs around 8 people.
The IPO was on 08/02/2021; the stock trades on NASDAQ under the ticker NGEN.
What do analysts say about NervGen Pharma stock?
1 analysts rate the stock, the consensus is Buy (as of 14/07/2026).
The average price target is US$12.00, ranging from US$12.00 to US$12.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does NervGen Pharma report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -22% stronger than usual.
Does NervGen Pharma pay a dividend?
No, NervGen Pharma currently does not pay a dividend.
Which stocks are comparable to NervGen Pharma?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get NervGen Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess NervGen Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.